Provided by the Academy for Continued Healthcare Learning
Supported by an educational grant from Novartis Pharmaceuticals Corporation
Heart failure (HF) affects 5.7 million adults in the United States and its prevalence is predicted to increase to 8 million adults by 2030. This disease is accompanied by a high mortality rate of 20% to 30% and a high rehospitalization rate. To this end, the ACC/AHA/HFSA issued a focused guideline update on HF in 2016 in light of two new, FDA-approved therapies: valsartan/sacubitril, an angiotensin receptor-neprilysin inhibitor (ARNI), and ivabradine, a sinoatrial node modulator.
In this activity, three expert faculty intersect problem-based learning with evidence-based medicine to help learners incorporate newly issued guideline updates into clinical practice. Learners will gain knowledge and competence regarding optimizing therapy strategies and improving patient outcomes in HF.
This educational activity is designed for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, and nurses involved in the care and treatment of patients with HF.
Upon completion of this activity, participants will be able to:
Explore current evidence-based guideline recommendations for pharmacological management of heart failure
Interpret recent clinical trial findings with new therapies for heart failure
Formulate appropriate heart failure therapeutic strategies based on the patient’s disease status and other related diagnostic factors, comorbidities, and individual needs
Discuss the importance of care coordination and transition for improving clinical outcomes in patients with heart failure
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Peter Carson, MD Professor of Medicine Georgetown University Chief, Coronary Care Unit Washington VA Medical Center Washington, DC
Dr. Carson discloses the following: Committee Member: Novartis Pharmaceuticals Corporation
Navin K. Kapur, MD Associate Professor of Medicine Executive Director of Research and Innovation The Cardiovascular Center at Tufts Medical Center Boston, MA
Dr. Kapur discloses the following: Consulting: Abiomed, Boston Scientific Corporation, Cardiac Assist, HeartWare, St. Jude Medical/Thoratec Sources of Funding for Research: Abiomed, Boston Scientific Corporation, Cardiac Assist, HeartWare, St. Jude Medical/Thoratec Speaker: Abiomed, Boston Scientific Corporation, Cardiac Assist, HeartWare, St. Jude Medical/Thoratec
Ileana L. Piña, MD, MPH Professor of Medicine Professor of Epidemiology and Population Health Director of Cardiology Montefiore Medical Center Bronx, NY
Dr. Piña has nothing to disclose.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take 60 minutes to complete. To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Laurie Novoryta ACHL Senior Program Manager Lnovoryta@achlcme.org